ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,090.27
      0.25%
      US Tech 100
      21,038.00
      0.79%
      Dow Jones
      44,642.52
      -0.28%
      Brent Oil
      70.95
      0.00%
      Bitcoin
      99,969.94
      0.05%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Immutep Ltd (IMMP) Quote

      Immutep Ltd

      Immutep Ltd (IMMP)

      NASDAQ
      2.09
      0.16
      (8.29%)
      Closed December 08 4:00PM
      Delayed by 15 minutes
      2.09
      0.00
      (0.00%)
      After Hours: 7:50PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      2.09
      Bid
      2.01
      Ask
      2.09
      Volume
      205,543
      2.01 Day's Range 2.14
      0.00 52 Week Range 0.00
      Market Cap
      304.005M
      Previous Close
      1.93
      Open
      2.06
      Last Trade
      100
      @
      2.09
      (formt)
      Last Trade Time
      Financial Volume
      $ 425,220
      VWAP
      2.0688
      Average Volume (3m)
      -
      Shares Outstanding
      145,456,785
      Dividend Yield
      -
      PE Ratio
      -1.12
      Earnings Per Share (EPS)
      -0.29
      Revenue
      -
      Net Profit
      -42.72M

      About Immutep Ltd

      Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesse... Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.immutep.com
      Headquarters
      Sydney, New South Wales, Aus
      Founded
      -
      Immutep Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IMMP. The last closing price for Immutep was $1.93. Over the last year, Immutep shares have traded in a share price range of $ 0.00 to $ 0.00.

      Immutep currently has 145,456,785 shares outstanding. The market capitalization of Immutep is $280.73 million. Immutep has a price to earnings ratio (PE ratio) of -1.12.

      Ask ADVFN Intelligence (AI)

      IMMP Latest News

      More News

      Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

      Media Release Mature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and exceeding expectations: Median Overall Survival is...

      November 14 2024
      GlobeNewswire Inc.

      Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

      Media Release Efti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients with soft tissue sarcomaOver three-fold increase in...

      November 14 2024
      GlobeNewswire Inc.

      Immutep Quarterly Activities Report Q1 FY25

      Positive feedback received from US FDA regarding the planned TACTI-004 Phase III in first-line non-small cell lung cancer successfully concluding regulatory preparations for the trial designEfti...

      October 29 2024
      GlobeNewswire Inc.

      Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

      Media Release SYDNEY, AUSTRALIA, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

      October 28 2024
      GlobeNewswire Inc.

      Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

      Media Release First safety data anticipated before year end with assessment of PK/PD relationships to follow in H1’CY2025 SYDNEY, AUSTRALIA, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited...

      October 17 2024
      GlobeNewswire Inc.

      Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

      Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

      October 10 2024
      GlobeNewswire Inc.

      Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

      Media Release SYDNEY, AUSTRALIA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...

      October 03 2024
      GlobeNewswire Inc.

      Immutep Receives A$3.6 million R&D Tax Incentive from French Government

      Media Release SYDNEY, AUSTRALIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related...

      September 24 2024
      GlobeNewswire Inc.

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      September 24 2024
      Edgar (US Regulatory)

      New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

      Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024 Annual MeetingEFTISARC-NEO is the first trial to...

      September 18 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      UPCUniverse Pharmaceuticals Inc
      $ 3.38
      (221.90%)
      		93.72M
      LIFWMSP Recovery Inc
      $ 3.2461
      (104.16%)
      		29.08M
      GXAIGaxos ai Inc
      $ 2.5801
      (81.70%)
      		146.21M
      SBETSharpLink Gaming Inc
      $ 0.9116
      (73.97%)
      		27.09M
      HCTIHealthcare Triangle Inc
      $ 1.165
      (68.38%)
      		4.34M
      ORISOriental Rise Holdings Ltd
      $ 3.6833
      (-93.42%)
      		27.58M
      LICNLichen China Limited
      $ 0.4895
      (-76.91%)
      		186.02M
      MYNAMynaric AG
      $ 0.499246
      (-64.59%)
      		3.62M
      CEROCERo Therapeutics Holdings Inc
      $ 0.1146
      (-40.16%)
      		38.21M
      BTCTBTC Digital Ltd
      $ 10.50
      (-32.95%)
      		3.31M
      SMXSMX Security Matters Public Company
      $ 0.4879
      (64.06%)
      		448.58M
      SOUNSoundHound AI Inc
      $ 15.01
      (12.60%)
      		218.94M
      NVDANVIDIA Corporation
      $ 142.44
      (-1.81%)
      		187.57M
      LICNLichen China Limited
      $ 0.4895
      (-76.91%)
      		186.02M
      SVMHSRIVARU Holding Ltd
      $ 0.0293
      (-16.29%)
      		162.46M

      IMMP Discussion

      View Posts
      Monksdream Monksdream 3 months ago
      IMMP 10 day hourly
      👍️0
      Monksdream Monksdream 5 months ago
      IMMP under $2
      👍️0
      Vector2112 Vector2112 5 months ago
      Refinitiv Logo
      As of 06/27/2024

      SellUnderperformHoldOutperformSelected Value:Buy
      Refinitiv Stock Reports Plus
      Refinitiv maintains a current price target of $8.64 for IMMP.
      👍️0
      glenn1919 glenn1919 5 months ago
      IMMP......................https://stockcharts.com/h-sc/ui?s=IMMP&p=W&b=5&g=0&id=p86431144783
      👍️0
      Monksdream Monksdream 5 months ago
      IMMP under $2
      👍️0
      Monksdream Monksdream 7 months ago
      IMMP under $3
      👍️0
      Monksdream Monksdream 1 year ago
      IMMP under $2
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      strong
      👍️0
      The Night Stalker The Night Stalker 1 year ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      ready
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      strong
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      watching
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      watching
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      dip
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      dip
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      nice
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      im in my bio DRMA, one at a time


      RIGL rip for more
      👍️0
      The Night Stalker The Night Stalker 2 years ago
      beast
      👍️0
      DewDiligence DewDiligence 2 years ago
      IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

      https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

      IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

      BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

      Please see #msg-168259768 for related info.
      👍️0
      Invest-in-America Invest-in-America 2 years ago
      IMMP: Very likely the hands-down WINNER of this Wall Street day, Peeps!!! (Just when ya thought that CANCER was no longer TRENDING.)

      👍️0
      stocks2watch stocks2watch 3 years ago
      Going to move up
      👍️0
      make it happen make it happen 4 years ago
      It's cool covered most average was $3.68
      👍️0
      calahan67 calahan67 4 years ago
      I think you're not taking into account whats in the pipeline mainly several studies involving much larger pharmaceutical interested the immune boosting properties of eftaligamod. Imo this company and ceo are the real deal. Forget the outlays and remember its research and development that costs the most up front no matter what pharm you're talking about
      👍️0
      make it happen make it happen 4 years ago
      More debt than revenue, large negatives on everything (cash flow, returns and profit margins.

      Profitability
      Profit Margin 0.00%
      Operating Margin (ttm) -300.79%

      Management Effectiveness
      Return on Assets (ttm) -20.00%
      Return on Equity (ttm) -61.68%

      Income Statement
      Revenue (ttm) 6.35M
      Revenue Per Share (ttm) 0.14
      Quarterly Revenue Growth (yoy) -76.90%
      Gross Profit (ttm) -6.66M
      EBITDA -17.07M
      Net Income Avi to Common (ttm) -27.36M
      Diluted EPS (ttm) -0.4500

      Total Debt (mrq) 9.75M
      Book Value Per Share (mrq) 0.94

      Cash Flow Statement
      Operating Cash Flow (ttm) -14.67M
      Levered Free Cash Flow (ttm) -7.67M
      👍️0
      sgunderbarth sgunderbarth 4 years ago
      IMMP Interesting action....
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $IMMP Video Chart 04-08-2021 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      make it happen make it happen 4 years ago
      Any positives in the numbers? Decent news but will need to raise money to keep anything going imho

      IMMP is "ELIGIBLE" to receive development based milestones and sales based royalties. They do not have sales and drug is not out.


      Profitability
      Profit Margin 0.00%
      Operating Margin (ttm) -300.79%

      Management Effectiveness
      Return on Assets (ttm) -20.00%
      Return on Equity (ttm) -61.68%

      Income Statement
      Revenue (ttm) 4.85M
      Revenue Per Share (ttm) 0.11
      Quarterly Revenue Growth (yoy) -76.90%
      Gross Profit (ttm) -6.66M
      EBITDA -13.03M
      Net Income Avi to Common (ttm) -20.89M
      Diluted EPS (ttm) -0.4600

      Balance Sheet
      Total Cash Per Share (mrq) 0.65 will blow through it and need a serious capital raise imho
      Total Debt (mrq) 7.45M
      Book Value Per Share (mrq) 0.71

      Cash Flow Statement
      Operating Cash Flow (ttm) -11.2M
      Levered Free Cash Flow (ttm) -5.86M
      👍️0
      make it happen make it happen 4 years ago
      Had R/S a couple years ago and was $0.53 about a year ago
      👍️0
      make it happen make it happen 4 years ago
      Quarterly growth -76.9%, returns are negative, zero profit and cash flow is very negative.

      Profitability
      Profit Margin 0.00%
      Operating Margin (ttm) -300.79%

      Management Effectiveness
      Return on Assets (ttm) -20.00%
      Return on Equity (ttm) -61.68%

      Income Statement
      Revenue (ttm) 4.85M
      Revenue Per Share (ttm) 0.11
      Quarterly Revenue Growth (yoy) -76.90%
      Gross Profit (ttm) -6.66M
      EBITDA -13.03M
      Net Income Avi to Common (ttm) -20.89M
      Diluted EPS (ttm) -0.4600

      Balance Sheet
      Total Cash Per Share (mrq) 0.65
      Total Debt (mrq) 7.45M
      Book Value Per Share (mrq) 0.71

      Cash Flow Statement
      Operating Cash Flow (ttm) -11.2M
      Levered Free Cash Flow (ttm) -5.86M
      👍️0
      make it happen make it happen 4 years ago
      I agree it states that Novartis is in chagre and IMMP is "ELIGIBLE" to receive milestones and payments. Previous reverse split. IMHO prob going to be bled
      👍️0
      reverse_long reverse_long 4 years ago
      IMMP never holds any spikes. Every time it has fastrack or patent news it dumps away. It is the real deal to dump very hard. GLTA!
      👍️0
      calahan67 calahan67 4 years ago
      This is the real deal folks
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $IMMP Video Chart 03-25-2021 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      DewDiligence DewDiligence 4 years ago
      IMMP up on BMY's LAG-3 coattails: #msg-162784750.
      👍️0
      calahan67 calahan67 4 years ago
      And they have a very sharp ceo if you've seen any of their videos he tells it straight up imo
      👍️0
      calahan67 calahan67 4 years ago
      Up huge on no news a great big sleeper imo
      👍️0
      calahan67 calahan67 4 years ago
      Looks like accumulation is beginning a slow churn higher
      👍️0
      everything everything 4 years ago
      Interesting company, looks to be in reversal but dip opportunity may be in the works.
      👍️0
      akamaii akamaii 4 years ago
      Like it here
      👍️0
      lecorb lecorb 4 years ago
      $IMMP: TIPRANKS, SCORE, UPGRADE TO 10 OUTPERFORM! ANALIST RATINGS: PT: $6.50 MODERATE BUY! LOW: @5.50, MED:@6.50, HI: $8.00 Jason McCarthy Maxim Group 5 Stars target $8.00 ranking Buy analystAction Reiterated date 6 days ago Last calification.
      👍️0

      Your Recent History

      NASDAQ
      IMMP
      Immutep
      Delayed Upgrade Clock